In lean hyperlipidemic E3L.CETP mice, rimonabant prevents the development of atherosclerosis, which is explained by a decrease in hepatic very low density lipoprotein (VLDL) particle formation and an increase in VLDL turnover that lowers plasma non-HDL-C. Here, CETP is linked to atherosclerosis.